Chronic Obstructive Pulmonary Disease Drugs Market by Product and Geography - Forecast and Analysis 2021-2025

  • Published: Jul 2021
  • Pages: 120
  • SKU: IRTNTR70733
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The chronic obstructive pulmonary disease drugs market has the potential to grow by USD 5.63 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 5.68%.

The chronic obstructive pulmonary disease drugs market report extensively covers market segmentation by product (combination therapy and monotherapy) and geography (North America, Europe, Asia, and ROW) and potential market drivers that the vendors are capitalizing on to sustain profitable growth. Furthermore, read about the latest key findings on the post COVID-19 impact on the market from this report.

What will the Chronic Obstructive Pulmonary Disease Drugs Market Size be in 2021?

Chronic-Obstructive-Pulmonary-Disease-Drugs-Market-Market-Size-2020-2025

Browse TOC and LoE with selected illustrations and example pages of Chronic Obstructive Pulmonary Disease Drugs Market

 Get Your FREE Sample Now!

Chronic Obstructive Pulmonary Disease Drugs Market: Key Drivers and Trends

Key drivers such as the rising prevalence of COPD are notably supporting the chronic obstructive pulmonary disease drugs market growth. However, one of the foremost factors impeding market growth is low diagnosis rates for COPD. Get detailed insights on the trends and challenges to stay prepared for the obstacles in the future, which will help companies analyze and develop growth strategies.

This post-pandemic chronic obstructive pulmonary disease drugs market report has assessed the shift in consumer behavior and identified trends and drivers that will help market players outmaneuver challenges. Technology innovations, implementation, and improvisation scope identified in the chronic obstructive pulmonary disease drugs market trends is essential for building new business opportunities across segmentations and geographies.

Who are the Major Chronic Obstructive Pulmonary Disease Drugs Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Exela Pharma Sciences LLC 
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Novartis AG
  • SHIONOGI Co. Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

 

From our Porter’s five forces analysis study, get detailed insights on the functional involvement of the buyers and suppliers to form well-rounded knowledge about the supply chain and create cost reduction plans. The chronic obstructive pulmonary disease drugs market analysis report also contains exhaustive observations on the organic and inorganic growth strategies deployed by the vendors. Click here to uncover details of successful business strategies adopted by the vendors.

Furthermore, our research experts have outlined the magnitude of the economic impact on each segment and recovery expectations post-pandemic. To recover from post COVID-19 impact, market vendors should create strategies to grab business opportunities from the fast-growing segments, while refining their scope of growth in the slow-growing ones.

Download a free sample of the chronic obstructive pulmonary disease drugs market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Which are the Key Regions for Chronic Obstructive Pulmonary Disease Drugs Market?

Chronic-Obstructive-Pulmonary-Disease-Drugs-Market-Market-Share-by-Region-2020-2025

For more insights on the market share of various regions Request for a FREE sample now!

The chronic obstructive pulmonary disease drugs market size, share, & trends analysis report offers an up-to-date study of the geographical composition of the market. 47% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for chronic obstructive pulmonary disease drugs market in North America.

The report offers an up-to-date analysis of the geographical composition of the market. North America has been recording a significant growth rate and is expected to offer several growth opportunities to market vendors during the forecast period. Strong pipeline and new drug approvals will facilitate the chronic obstructive pulmonary disease drugs market growth in North America over the forecast period. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report.

What are the Revenue-generating Product Segments in the Chronic Obstructive Pulmonary Disease Drugs Market?

Chronic-Obstructive-Pulmonary-Disease-Drugs-Market-Market-Share-by-Product-2020-2025

To gain further insights on the market contribution of various segments Request for a FREE sample!

The chronic obstructive pulmonary disease drugs market report provides a comprehensive understanding of the subsets of our target market to earmark niche customer groups and simplify demographic requirements. In addition, the report provides insights on the impact of the unprecedented outbreak of COVID-19 on market segments. Through these insights, you can safely deduce transformation patterns in consumer behavior, which is crucial to gauge segment-wise revenue growth during 2021-2025 and embrace technologies to improve business efficiency. The chronic obstructive pulmonary disease drugs market share growth by the combination therapy segment has been significant and is expected to provide significant growth opportunities to market vendors.

This report provides thorough chronic obstructive pulmonary disease drugs market segment analysis that will help you gauge the existing competition, demographics, lucrative target customer groups, solutions to improve sales and services, and other crucial market intelligence data. Request for a free sample of the report to get an exclusive glimpse of actionable market insights on post COVID-19 impact on each segment and the growth of the chronic obstructive pulmonary disease drugs market size.

 

Event-Tickets-Market-Report

Request for a FREE sample

What are the Key Factors Covered in this Chronic Obstructive Pulmonary Disease Drugs Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive chronic obstructive pulmonary disease drugs market growth during the next five years
  • Precise estimation of the chronic obstructive pulmonary disease drugs market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the chronic obstructive pulmonary disease drugs market across North America, Europe, Asia, and ROW 
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of chronic obstructive pulmonary disease drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Chronic Obstructive Pulmonary Disease Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 5.68%

Market growth 2021-2025

$ 5.63 billion

Market structure

Concentrated

YoY growth (%)

5.50

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 47%

Key consumer countries

US, UK, Canada, Germany, and Japan

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AstraZeneca Plc, Exela Pharma Sciences LLC , GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, SHIONOGI Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, and Viatris Inc.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025

    Five Forces Analysis

    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Product

    • Market segments
    • Comparison by Product
    • Combination therapy - Market size and forecast 2020-2025
    • Monotherapy - Market size and forecast 2020-2025
    • Market opportunity by Product

    Customer landscape

      Geographic Landscape

      • Geographic segmentation
      • Geographic comparison
      • North America - Market size and forecast 2020-2025
      • Europe - Market size and forecast 2020-2025
      • Asia - Market size and forecast 2020-2025
      • ROW - Market size and forecast 2020-2025
      • Key leading countries
      • Market opportunity by geography
      • Market drivers
      • Market challenges
      • Market trends

      Vendor Landscape

      • Overview
      • Vendor landscape
      • Landscape disruption

      Vendor Analysis

      • Vendors covered
      • Market positioning of vendors
      • AstraZeneca Plc
      • Boehringer Ingelheim International GmbH
      • Exela Pharma Sciences LLC 
      • GlaxoSmithKline Plc
      • Merck and Co. Inc.
      • Novartis AG
      • SHIONOGI Co. Ltd.
      • Sumitomo Dainippon Pharma Co. Ltd.
      • Teva Pharmaceutical Industries Ltd.
      • Viatris Inc.

      Appendix

      • Scope of the report
      • Currency conversion rates for US$
      • Research methodology
      • List of abbreviations

      Research Framework

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      TechnavioINFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases
      Technavio

      TechnavioDATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts
      Technavio

      TechnavioREPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape
      Interested in this report?
      Get your FREE sample now!
      The chronic obstructive pulmonary disease drugs market growth will increase by $5637.38 million during 2020-2025.
      The chronic obstructive pulmonary disease drugs market is expected to grow at a CAGR of 5.68% during 2020-2025.
      Technavio has segmented the chronic obstructive pulmonary disease drugs market by product (Combination therapy and Monotherapy) and geographic (North America, Europe, Asia, and ROW).
      AstraZeneca Plc, Boehringer Ingelheim International GmbH, Exela Pharma Sciences LLC , GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, SHIONOGI Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc. are a few of the key vendors in the chronic obstructive pulmonary disease drugs market.
      North America will register the highest growth rate of 47.12% among the other regions. Therefore, the chronic obstructive pulmonary disease drugs market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
      The key factors driving the chronic obstructive pulmonary disease drugs market growth are:
      • Rising prevalence of COPD
      • Expanding research in curative approaches
      The chronic obstructive pulmonary disease drugs market vendors should focus on grabbing business opportunities from the combination therapy segment as it accounted for the largest market share in the base year.
      Safe and Secure SSL Encrypted
      Technavio

      Single User:

      2500 USD

      Technavio Get the report (PDF) sent to your email within minutes.

      Subscribe & Save

      Get lifetime access to our
      Technavio Insights

      Want to customize this report?

      This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

      We offer $1000 worth of FREE customization at the time of purchase
      Technavio
      Enquire Before Buying
      1. Home
      2. Health Care
      3. Published Report
      17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>